Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up – Should You Buy?

Maplight Therapeutics, Inc. (NASDAQ:MPLT) gapped up before the market opened on Monday . The stock had previously closed at $12.99, but opened at $13.99. Maplight Therapeutics shares last traded at $13.64, with a volume of 2,150 shares.

Wall Street Analyst Weigh In

MPLT has been the topic of several recent analyst reports. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Leerink Partnrs raised Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Morgan Stanley began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $31.00.

Maplight Therapeutics Stock Performance

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.